

Q4 2015 results – 18 February 2016

David Nuutinen, CEO
Danko Maras, CFO
Jacob Broberg, SVP IR

Q4 highlights

Strong cash flow, decreased debt and proposed dividend

- Net sales for the quarter increased by 2.7 per cent to SEK 1,622m (1,579). For the full year 2015 net sales increased by 6.8 per cent to SEK 5,674m (5,313).
- Operating profit was SEK 239m (262). For the full year 2015 operating profit improved to SEK 671m (577).
- Operating profit, adjusted was SEK 255m (257). For the full year 2015 operating profit, adjusted improved to SEK 690m (632).
- Cash flow from operating activities improved to SEK 367m (290). For the full year cash flow from operating activities improved to SEK 927m (500).
- Net debt/EBITDA was 3.03x (3.97).
- The Board proposes a dividend of SEK 0.50 (-) per share.





Overall market and sales development

Total sales growth of 2.7 per cent

 Positive to flat total market developments, except seasonal products in Italy

Organic growth -2.3 per cent for the quarter.
 Excluding Italy, organic growth was 1.8 per cent

 Sales grew or was unchanged in all markets except Italy, Denmark and UK.

 Positive sales trend in Sweden and Finland driven by pick-and-mix.

In Denmark sales of pastilles declined.

 Decline in Italy driven by a sharp decrease in seasonal sales due to price increases to off-set raw material price increases.







Net sales and EBIT

| SEKm | Oct-Dec 2015 | Margin % | Change % | Oct-Dec 2014 | Margin % | Full year 2015 | Full year 2014 |
|----------------------------|-----------------|-------------|-------------|-----------------|-------------|-------------------|-------------------|
| Net sales | 1,622 | | 2.71 | 1,579 | | 5,674 | 5,313 |
| Operating profit, adjusted | 255 | 15.7 | -0.8 | 257 | 16.3 | 690 | 632 |
| Operating profit (EBIT) | 239 | 14.7 | -8.8 | 262 | 16.6 | 671 | 577 |
| Profit for the period | 157 | | -0.6 | 158 | | 386 | 242 |

1) Organic growth at constant exchange rates and comparable units -2.3% for the quarter and 1.5% for the year.





Changes in net sales


| Changes in net sales, % | Oct-Dec 2015 | Oct-Dec 2014 | Full year 2015 | Full year 2014 |
|---------------------------|-----------------|-----------------|-------------------|-------------------|
| Organic growth | -2.3% | 1.7% | 1.5% | 1.0% |
| Structural changes | 4.8% | 4.8% | 3.9% | 4.3% |
| Changes in exchange rates | 0.2% | 3.1% | 1.4% | 3.3% |
| Total | 2.7% | 9.6% | 6.8% | 8.6% |








Net sales, Operating profit (EBIT) and Operating profit, adjusted







Strong cash flow from operating activities







Cash flow


| SEKm | Oct-Dec 2015 | Oct-Dec 2014 | Full year 2015 | Full year 2014 |
|------------------------------------------------------------------------------------|-----------------|-----------------|-------------------|-------------------|
| Cash flow from operating activities before changes in working capital | 295 | 267 | 697 | 492 |
| Cash flow from changes in working capital | 72 | 23 | 230 | 8 |
| Cash flow from operating activities | 367 | 290 | 927 | 500 |
| Cash flows from investments in property, plant and equipment and intangible assets | -48 | -64 | -161 | -182 |
| Cash flow from other investing activities | - | 4 | -206 | -187 |
| Cash flow from investing activities | -48 | -60 | -367 | -369 |
| Cash flow from operating and investing activities | 319 | 230 | 560 | 131 |
| Cash flow from financing activities | -211 | -114 | -518 | -24 |
| Cash flow for the period | 108 | 116 | 42 | 107 |





Financial leverage

Net debt/EBITDA, x







Cloetta stands strong

Dividend of SEK 0.50 (-) per share proposed

- Improved EBITDA and very strong cash flow for the year.
 - Cash flow from operating activities improved to SEK 927m (500).
- Net debt/EBITDA decreased to 3.03x (3.97).
 - Well on track towards the target of Net debt/EBITDA of 2.5x
- The Board proposes a dividend of SEK 0.50 (-) per share
- Ambition is to use future cash flows for repayment of debts and payment of share dividend, while at the same time providing financial flexibility for complementary acquisitions.





Integration of Lonka according to plan

Will in 2017 support Cloetta's margin target of 14%

- Decision to close the factory in Dieren, the Netherlands and transfer production to Levice, Slovakia
 - One-off costs and capital investments of approximately SEK 120m
- Joint sales and marketing organisation created in the Netherlands
- Savings from the closure of the factory in Dieren, insourcing of production and synergies will generate savings of at least SEK 35m
- Plans for how to operate and launch Lonka in other markets finalised








In focus













Q4 selection of product launches

Italy







The Netherlands





KING

chew

Finland







Sweden





KING

chew











Switzerland





Q&A

Cloetta

Disclaimer

- This presentation has been prepared by Cloetta AB (publ) (the "Company") solely for use at this presentation and is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. The presentation does not constitute an invitation or offer to acquire, purchase or subscribe for securities. By attending the meeting where this presentation is made, or by reading the presentation slides, you agree to be bound by the following limitations.
- This presentation is not for presentation or transmission into the United States or to any U.S. person, as that term is defined under Regulation S promulgated under the Securities Act of 1933, as amended.
- This presentation contains various forward-looking statements that reflect management's current views with respect to future events and financial and operational performance. The words "believe," "expect," "anticipate," "intend," "may," "plan," "estimate," "should," "could," "aim," "target," "might," or, in each case, their negative, or similar expressions identify certain of these forward-looking statements. Others can be identified from the context in which the statements are made. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which are in some cases beyond the Company's control and may cause actual results or performance to differ materially from those expressed or implied from such forward-looking statements. These risks include but are not limited to the Company's ability to operate profitably, maintain its competitive position, to promote and improve its reputation and the awareness of the brands in its portfolio, to successfully operate its growth strategy and the impact of changes in pricing policies, political and regulatory developments in the markets in which the Company operates, and other risks.
- The information and opinions contained in this document are provided as at the date of this presentation and are subject to change without notice.
- No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information contained herein. Accordingly, none of the Company, or any of its principal shareholders or subsidiary undertakings or any of such person's officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

